ArticleCancer medicine2018
Positive predictive values of fecal immunochemical tests used in the STOP CRC pragmatic trial.
Article in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- Mailed Outreach for Colorectal Cancer Screening in Community Health Centers: The CARES Pragmatic Cluster Randomized Clinical Trial.JAMA internal medicine · 2026Trial
- Prospective Cohort study of Predictors of Follow-Up Diagnostic Colonoscopy from a Pragmatic Trial of FIT Screening.Scientific reports · 2020Trial
- Serum untargeted metabolomics analysis of colorectal cancer.BMC cancer · 2025Article
- Beyond colonoscopy, faecal DNA mutation screening provides a potential and viable path to early colorectal cancer detection.Scientific reports · 2025Article
- New Insights into Colorectal Cancer through the Lens of Precision Oncology and Personalized Medicine: Multi-Omics Helps Aging of Predisposed People.Current aging science · 2025Review
- Review
- Feasibility and efficacy of a novel audiovisual tool to increase colorectal cancer screening among rural Appalachian Kentucky adults.Frontiers in public health · 2024Article
- Costs and outcomes of colorectal cancer screening program in Isfahan, Iran.BMC health services research · 2023Article
- The Diagnostic Accuracy of a Fecal Immunochemical Test in Detecting Colorectal Cancer and Advanced Precancerous Colorectal Neoplasia in Patients with Iron Deficiency: A Protocol for Systematic Review and Meta-Analysis.Gastroenterology research and practice · 2023Article
- Urine NMR Metabolomics for Precision Oncology in Colorectal Cancer.International journal of molecular sciences · 2022Review
- Predictive Modeling of Colonoscopic Findings in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program.Digestive diseases and sciences · 2022Article
- Source matters: a survey of cost variation for fecal immunochemical tests in primary care.BMC health services research · 2022Article
- Identification and management of pragmatic clinical trial collateral findings: A current understanding and directions for future research.Healthcare (Amsterdam, Netherlands) · 2021Article
- Stakeholder perspectives regarding pragmatic clinical trial collateral findings.Learning health systems · 2021Article
- Comprehensive Volatilome and Metabolome Signatures of Colorectal Cancer in Urine: A Systematic Review and Meta-Analysis.Cancers · 2021Review
- The Roadmap of Colorectal Cancer Screening.Cancers · 2021Review
- Patients' Views About the Disclosure of Collateral Findings in Pragmatic Clinical Trials: a Focus Group Study.Journal of general internal medicine · 2020Article
- Article
- Ethics and Collateral Findings in Pragmatic Clinical Trials.The American journal of bioethics : AJOB · 2020Article
- Positive predictive values of fecal immunochemical tests used in the STOP CRC pragmatic trial.Cancer medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
Annual fecal immunochemical testing (FIT) is cost-effective for colorectal cancer (CRC) screening. However, FIT positivity rates and positive predictive value (PPV) can vary substantially, with false-positive (FP) results adding to colonoscopy burden without improving cancer detection. Our objective was to describe FIT PPV and the factors associated with FP results among patients undergoing CRC screening. In an ongoing pragmatic clinical trial of mailed-FIT outreach, clinics delivered one of three FIT brands (InSure, OC-Micro, and Hemosure). Patients who had a positive FIT result and a follow-up colonoscopy were included in this analysis (N = 1130). Patients' demographic and medical histories were abstracted from electronic health records (EHR). Associations with a FP result (ie, a positive FIT result with no evidence of advanced neoplasia during follow-up colonoscopy) were evaluated for FIT brand and patient factors using mixed-effects multivariable logistic regression. The mean proportion of FIT-positive results ranged from 8% in centers using the OC-Micro test to 21% for Hemosure. PPVs for advanced neoplasia were 0.30 to 0.17, respectively (P for χ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.